In this issue:

**Melanoma**  
European Parliament meeting  
Page 3

**Dermatology in Europe**  
Dermatology in Bosnia & Herzegovina  
Page 8

**Election of EADV President-Elect**  
Meet the candidates  
Page 14

**European Dermato-epidemiology Network**  
Collaborative projects  
Page 18

---

**Beyond Fashion**  
Paris welcomes the 17th EADV Congress  
17–21 September 2008  
Page 4
EADV
PARIS 2008
PALAIS DES CONGRÈS
17 - 21 SEPTEMBER 2008
17th CONGRESS OF THE EUROPEAN ACADEMY
OF DERMATOLOGY AND VENEREOLOGY

www.eadvparis2008.com
Collaboration leads to empowerment

We all like to be thought of as independent, active individuals who control our own destiny. In economic terms, traditional theory suggests that the most efficient society is created for the greater common good, when we act as informed rational entities, which make informed choices and take responsibility for our actions.

Over the last few decades the idea of the patient as consumer has therefore been advocated. This would imply several changes. Traditionally, patients are seen as passive and dependent, whereas consumers are more active and rational, always seeking optimum returns on their investment. The advocates of such changes believe that a more consumerist attitude among patients will lead to more effective healthcare as patients take greater responsibility for their health, thereby liberating resources in the healthcare system hitherto bound in paternalistic care. By liberating the patients you may also liberate the organisation.

The life of an organisation is however dependent on many things. The tasks at hand play a role, as do structure, membership and leadership. The EADV is a constantly evolving organisation dedicated to the science of dermatology, and this year is no different from other years. As we grow both in members and stature, new challenges and opportunities arise, to which the Academy adapts on all levels. In this issue you are presented with information that will be helpful to you when you vote for a new president later this year.

The consumerist view of patients has implications for the organisation, but it also has implications for the individual patient. Choice and responsibility are Siamese twins. The consumerist patient therefore has to carry more responsibility; and when you ask patients it not clear that this is what they want. What patients want is a close collaboration with an expert who can guide them in their management of disease. They are neither interested in paternalistic care. By liberating the patients you may also liberate the organisation.

Similarly, you may notice, with organisations. Providing structure and leadership is one thing, but it does not work without the involvement of the membership. Not only though voting, but through participation in the life of the organisation.

Gregor Jemec
Editor
Dear colleagues and members of the EADV,

After the Istanbul Symposium, the meetings of the EC, the Board, the Committees, the presidents of the national societies and the EGM, I can say (and I think this is also the opinion of the majority) that we have made an important advance in the organisation and in the development of the Society.

First of all I would like to underline that the work and the debate between different opinions in the single sessions and in the Board took place in an atmosphere of friendliness, mutual comprehension and respect. It should also be noted that before Istanbul a very intense and open mail discussion had been developed between Frank Powell, Joe Pace, Walter Cassola, other members of the EC and myself, but also involving the members of the Board, which led to a preliminary clarification of potentially controversial aspects regarding the suggested modifications of the Statutes.

Focus on education

The different options, the advantages and the disadvantages, the possible risks (mentioned with his usual clarity by Frank Powell, Committee Chairman) have been closely examined and I must express my thankfulness to all (but in particular to the Secretary General Joe Pace) for the intense activity carried out in a cooperative and serene spirit, which demonstrated the heartfelt wish of contributing to the growth and the success of EADV. It was cleared up and subscribed to by everyone that the main aim of EADV is the educational activity, represented by the fostering activities. Obviously this is possible only if the Society has at its disposal an adequate budget, which the fiscal authorities from Lugano (as is the case for all Swiss cantons and not only for the Ticino canton) can help to guarantee, assuring us a condition of non-taxation if in the Statutes it is clearly indicated that EADV pursues aims of “public utility” and if the organisation of our activities takes place in Lugano (in other words if the PCO activity is carried out directly by EADV).

The documented interventions by our lawyer, Walter Cassola, the Treasurer, Jon Olafsson and other EC members have been precise and effective and persuaded the great majority of the Board members of those who voted directly or electronically to endorse the changes in the Statutes. These changes had to be undertaken with urgency in order to put the administrative situations of 2006 and 2007 right. Obviously we now have to perfect what has been approved and we have to define completely our operative attitude.

The Board meeting was completed by the interventions of the presidents (or their delegates) of the national societies which had accepted to subscribe their members to the EADV as supporting members. For everyone this has been perceived as an important moment since it marks the real beginning of a common path aimed at facing in a clear way - and possibly with a common strategy - the problems linked to our discipline and encountered by European dermatologists.

It is clear that the more numerous we are (and now we are numerous) the more weight we will have in our relationships with the political authorities, the scientific societies and the pharmaceutical companies. Moreover we will also be able to represent with even a greater force the interests of dermatological patients in cooperation with their associations. We will have to make a special effort, establishing a calendar of priorities and interventions, to
develop common projects and to formulate shared solutions.

Istanbul confirmed that many countries on the borders with Europe are looking at EADV with great interest as a great society for a clinical/scientific co-operation of mutual benefit. For this reason I appeal once again to all members - and especially to the newly subscribed ones - for your active contribution to the activities of the Society: the task forces are waiting for you.

It is unavoidable that an increase in EADV’s subscriptions leads to the opportunity of changing the structures of the communication means and activities of the Society. Therefore, EADV News and the website could be reorganised in order to meet new requests.

**Growth and progress**

Meanwhile, I remember with pleasure that the fostering activity will be intensively developed in the coming months, with courses for residents on lymphoma in Copenhagen, with summer schools on STD in Sofia, and on dermatopathology in Graz, and with courses for practitioners (also open to residents) on lasers in Geneva and on hand and facial dermatitis in Brussels in September, with the final meetings on dermatoscopy in Modena.

In Istanbul, Verona and Karlovy vary presented their bidding for the Spring Symposium of 2011: two excellent locations, on which we will have to make a choice after the results of the site visits.

Istanbul has been a real success for the number of participants, the quality of the lectures and the numerous attendants... except on Saturday, on which the overwhelming desire of visiting the beautiful city on a wonderful day prevailed. But this is a common problem typical of the last day of many congresses. The convention centre perfectly housed the various sessions, including that of the spectacular opening ceremony. I would like to offer my sincere thanks to the President of the Congress, Professor Mehmet Ali Gürer and his colleagues.

We are now moving towards our appointment in Paris, sure that the ville lumière will welcome us with its usual fascination and its proven organisation. The Congress President, Pascal Joly, is doing his best to assure us the best possible hospitality. The scientific programme has been defined and is at the same level of our best congresses.

The election process for the election of EADV President will come to an end in Paris and the Board will vote for the General Secretary.

My best wishes to the candidates!

So, see you in Paris and have a nice summer.

Alberto Giannetti
EADV President
Paris, Capital of Fashion goes “Beyond Fashion”!

I am sure this title will sound a little strange to you: you are probably wondering why Paris, the capital of fashion, is going “Beyond Fashion”? No more haute couture? No more new trends? No, do not worry, nothing of the kind!

“Beyond Fashion” is the 2008 EADV Congress theme: a reminder that dermatologists have an obligation to work in accordance with a high standard of care and evidence-based medicine, beyond fashion.

We are now only three months away from the Congress and, like a jigsaw, every single piece has been gently placed next to the other keeping our theme in mind and giving shape to a prominent and multi-dimensional scientific programme which promises to be a powerful learning and sharing experience.

The past months have been decisive to fine-tune and enrich the programme with the successful call for abstracts which has generated over 2,000 papers from which 1,700 poster presentations and 17 free communications sessions have been selected, including a junior session dedicated to residents - not forgetting the two poster forums.

Altogether, the core programme comprises 142 sessions which have been frame-worked over three intense working days, bringing updates and creating debates on various fields and hot topics such as autoimmune bullous skin disorders, cutaneous lymphomas, skin cancers, cutaneous disorders of organ-transplant patients and many more.

Presentations are delivered by experts of the highest reputation and, in addition to the six plenary lectures, attendees will be able to tailor-make their programme and select their points of interest among 45 workshops, 29 symposia, 19 courses (including a live surgery one), and many other sessions such as:

- Interactive “Test Yourself” sessions (paediatric dermatology, internal medicine, contact dermatitis...).
- Forum sessions, such as “Dermatology: think differently” devoted to innovative ideas, preliminary data, and original opinions; “The best clinical studies from co-operation between academic and office-based dermatologists” and “The best clinical studies from European groups”.
- “What's new?” sessions addressing the latest findings and developments.

Enter the magic of the Arts Forains Museum, a unique venue, located close to the river Seine, where you will enjoy an exquisite dinner and a delightful evening of amusement and fun among one of the largest collections of authentic fairground objects, including roundabouts, carousels and all sorts of ancient toys.

The evening will provide an unforgettable ambiance, with fun rides, old-fashioned attractions, dancing and so on.

This dinner is optional; to sign up please refer to the Congress website registration page: www.eadvparis2008.com

Paris, la ville lumière

Make sure that, after the busy scientific sessions, you take some time off to wander around the city and soak up the Parisian atmosphere: stroll down its wide and magnificent boulevards, sit at a café and watch the crowds and trends go by, go crazy for some fashion shopping or just remain speechless while admiring the masterpieces at the Louvre.

Whatever your mood is, whatever you are keen on: just enjoy Paris your way and make the most of its art de vivre!

Remember that the Congress offers a wide selection of tours to discover Paris and other regions of France: check the list and conditions on the website: www.eadvparis2008.com

And do not miss the wonderful social events organised within the Congress time frame:

- The Opening Ceremony and Welcome Reception on Wednesday, 17 September 2008

The perfect time and place to meet friends, renew old acquaintanceships and make new ones while enjoying music and canapés in a convivial atmosphere!

Held in the Palais des Congrès, this event is included in participants’ and spouses’ registration fees.

- The Congress Dinner on Friday, 19 September 2008
The sub-specialty meetings which are scheduled on Wednesday, 17 September are also a great and essential part of the Congress, as well as the industry satellite symposia taking place over the four days. Impressive and exciting too are the variety and number of nationalities that are represented in the programme and among the attendees: more than 80 countries from all continents.

EADV is stretching out far beyond Europe’s boundaries: dermatologists and venereologists in demand worldwide for exchanges and co-operation have recognised the high scientific profile of its annual congress.

Let me just add a few words now about the wonderful city that is hosting the Congress: Paris synonymous with elegance and romance, history and culture, is waiting with open arms for your visit. And all you will have to do is to breathe it, taste it, watch it, feel it… your stay and visit will be simply magical!

EADV, the Local Organising Committee and the French community of dermatologists are doing their best to make the 17th EADV Congress a most memorable event and we look forward to welcoming you to Paris in September.

Pascal Joly
On behalf of the Local Organising Committee

Paris, practical and easy

Paris is offering visitors not only history and tradition but also modernity, excellent transportation and accommodation facilities.

Located at the crossroads of Europe, the city has two international airports, seven train stations and is linked to several motorways.

The metro pass you will receive with your registration on site will allow you to quickly reach the Palais des Congrès and move around downtown Paris by metro, bus and tram for the entire duration of the Congress.

Looking for a place to stay? All sorts of accommodation suiting any budget and taste can be found in all city areas. The Congress office can propose a large range of hotels but do not wait too long to book your room: remember that September is a very busy month in Paris, so please reserve your hotel as soon as you can.

Paris, Congress useful facts

Venue
The Congress will take place at the Palais des Congrès (Paris Convention Centre) which is ideally located in the western part of the capital, only 10 minutes away from the Champs-Élysées, the Arc de Triomphe or the Eiffel Tower. It is easily accessible: by car (Parking Porte Maillot under the Convention Centre), by local city buses (lines: 82, 73, 43, 244, PC), by metro (line 1) or by RER (Paris Suburban Express Metropolitan Network, line C). The welcome desks will be located on level 0 and the conference rooms on levels 1-2-3.

Key Dates
• Late registration deadline: 25 August 2008
• Opening of the Congress and Welcome Reception: 17 September 2008
• Congress Dinner: 19 September 2008

Registration
The next registration deadline is 25 August 2008; sign up before that date in order to benefit from the reduced fees.

Several registration categories are available for attendees and remember that the Congress is open to EADV members as well as non-members. A special registration fee is applied to accompanying persons.

To find out more and to book your place, please refer to the registration section of the website: www.eadvparis2008.com

Exhibition and sponsorship

The EADV Paris 2008 Exhibition will be held on three different levels of the Palais des Congrès, where pharmaceutical companies, laboratories and equipment providers will have ample space to show their products and technologies to an international and tightly focused audience.

More than 180 exhibitors and sponsors have chosen to be part of this dynamic exchange platform and highly professional environment. To learn more about exhibition and sponsorship options, please contact the Congress Office at: exhibition@eadvparis2008.com

Contact
EADV PARIS 2008, c/o MCI
24 rue Chauchat
75009 Paris - France
Tel.: +33 (0)1 53 85 82 70
Fax.: +33 (0)1 53 85 82 83

General information: info@eadvparis2008.com
Scientific programme: scientific@eadvparis2008.com
Exhibition and sponsorship: exhibition@eadvparis2008.com
Registration and accommodation: registration@eadvparis2008.com

For further information and to register: www.eadvparis2008.com
Dermatology is an “organ” specialty so we dermatologists have to attend to our patients’ complaints in the round, that is we have to establish diagnosis, prognosis, treatment and rehabilitation.

Dermatological surgery has a long tradition in our specialty and dermatologists invented surgical instruments and methods of treatment that gave powerful contributions to its development. To name just a few we will mention hair transplant, liposuction, tumescent anaesthesia and dermabrasion.

Our Task Force had its first formal meeting during the EADV Congress in Rhodes and we are planning to meet again in Paris (see box below).

During that Rhodes meeting we understood that there are a lot of differences regarding the practice of dermatological surgery in different European countries and also the teaching programmes during dermatological residency vary widely all over Europe.

It is our intention to find out more and to help build a solid training in dermatosurgery everywhere in Europe. We are, therefore, pleased to announce that one of our very active members, Dr Gertrud Krekels, is organising from 29-31 January 2009 a European course in dermatosurgery with live demonstrations of Mohs surgery in Eindhoven. Workshops on dermato-surgery and laser surgery will also be included. For further information please contact Dr Krekels at gertruud@erens-kerkels.net.

Dr António Picoto
Moderator
Task Force on Operative Dermatology

Here you can see two surgical interventions in the Centro de Dermatologia Medico-Cirurgica de Lisboa, one to extirpate a basal cell carcinoma and a rotation flap to close the defect after Mohs surgery, another to remove a melanoma and the closure.

The Task Force’s next meeting will take place during the Paris Congress on Saturday, 20 September at 09.30, immediately after the workshop on Mohs surgery.
A private practitioner's training report

“My name is Mihaela Costache, and I am a dermatologist working in a private practice in Arad, Romania. Because I wanted to improve my knowledge in dermato-surgery I applied for the EADV Education for Private Practitioners programme and I was very lucky to be accepted at Neukölln Clinic of Dermatology in Berlin run by Professor Peter Karl Kohl. I spent my time in the surgery room mainly with Chief Doctor Karl Grunow, who was in charge of dermato-surgery at Neukölln Clinic, but also with Professor Kohl and Dr Fabian Ziller. My training ranged from basic dermato-surgery (asepsy, suture materials, anaesthesia, small incisions) to doing flaps and skin grafts which I find very interesting and helpful for my future career.

Because this clinic treats many cases of skin tumours, including melanomas, I attended several sentinel lymph node biopsies. In addition to dermato-surgery I took part in the scientific activity of the clinic. Every Wednesday a lecture was held on dermatology, and on Mondays and Thursday Professor Kohl and the other doctors interested in dermatopathology gathered together to read slides from the patients of the clinic. I believe that dermato-surgery and dermatopathology are very important for a dermatologist and Professor Kohl told me from the first day I arrived there that a good dermatologist means a good clinician, a good skin surgeon and last but not least a good dermato-pathologist.

During my time spent at Neukölln Clinic, I enhanced a lot my skills in dermato-surgery and came back home more confident and willing to put into practice what I learned in Berlin.

I would like to express my thanks to Professor Kohl, Dr Grunow and Dr Ziller for teaching me and helping me during my stay there. I also thank Christine Bardeck, the secretary of the clinic and the others doctors for the warm welcome they gave me in Berlin.

Finally, I would like to express my gratitude to EADV for this wonderful opportunity for young doctors to be trained in Europe.”

EADV Education for Private Practitioners Programme

European Society of Dermatopathology (ESDP)

Founded
The ESDP was established in June 1996 in Zurich to focus on dermatopathology - the microscopic aspects of clinical dermatology.

Scope and Purpose
The aims are as follows:
- To educate by organising meetings, creating slide sets, and providing opportunities for trainees in pathology and dermatology to spend time in centres of dermatopathology of their choices.
- To establish a European Diploma of Dermatopathology, that is the equivalent of the Board examination in the United States and that which now exists in the United Kingdom. This diploma would be accessible to both pathologists and dermatologists.
- To enhance co-operation between pathologists and dermatologists interested in dermatopathology.
- To standardise quality criteria of performance in dermatopathology

Membership
The ESDP currently has 250 members. Membership provides access to all Society activities and a substantial discount subscription to the journal Dermatopathology – Practical and Conceptual.

Activities
The Society organises two meetings, one at the ESDR (European Society of Dermatological Research) meeting, more focused on the links between research and dermatopathology, and one at the EADV meeting, which is more orientated towards educational dermatopathology. At the EADV meeting the practical details of the European Board Certification of Dermatopathology (a yearly exam which takes place in Frankfurt in December) are also discussed. This exam is organised under the auspices of the UEMS and ESDP.

Further information
If you would like to become a member, please see the website: www.esdp.net
Or contact:
President: Bernard Cribier
bernard.cribier@chru-strasbourg.fr
Secretary: Carlo Francesco Tomasini
tomasini@molinette.piemonte.it
Country Name: Bosnia & Herzegovina
Capital: Sarajevo
Population: 4,552,198 inhabitants
Area: 50,000 km²
GDP per capita (2006): US$ 5,600
Number of dermatologists: 120

Dermatology in Bosnia & Herzegovina

History

The first written documents on medical treatment of skin diseases in Bosnia & Herzegovina date from 1866. At the time syphilis, leprosy, mycology and parasitic diseases were present. In 1885, when Bosnia & Herzegovina was under Austrian-Hungarian reign, Austrian physician Leopold Gluck was ordered by the Austrian-Hungarian authorities to come to Bosnia & Herzegovina and solve the problems of skin diseases. An article on statistics on etiology and prophylaxis of favus was left from that period.

In 1890, Professor Izidor Neuman arrived from Vienna to start working on repelling syphilis. At his instigation a hospital was opened in Sarajevo in 1894 as a precursor to the present Clinical Center of the University of Sarajevo, which is also a scientific base of the Medical Faculty of Sarajevo University. The Clinical Center marked its 100th anniversary in 2004. The first head of the Department for Syphilis and Skin Diseases was Leopold Gluck who had worked with Professor Hebre in Vienna before coming to Bosnia. In 1897, a leprosarium was established in Sarajevo, which was the first one of its kind in the Balkans.

In 1903, the 8th Congress of Austrian Dermatologists was held in Sarajevo and was chaired by Leopold Gluck. In 1907, he was succeeded by his son Alexander Gluck who had worked out the clinical description of syphilis and published the book titled Syphilis. The first serological laboratory for diagnosing syphilis was established. Professor Dr Ernest Grin, appointed as the WHO expert, has headed the Clinic for Dermato-venereology since 1966. The Clinic became the reference center for eradicating syphilis and fungous diseases in the territory of Bosnia & Herzegovina. The mycological laboratory is run by Professor Ozegovic. In the last 50 years the Clinic for Dermatovenereology with all its laboratories has continued to develop in the spirit of modern dermatology.

The recent war, initiated by Serbian aggression, that befell Bosnia & Herzegovina and occupied Sarajevo for five years entirely devastated the Clinic for

The Dermato-venereology Society of Bosnia & Herzegovina

The Society was established in 1996 and currently has 120 members. It has organised two allergy schools, one international conference (the first Bosnia & Herzegovina dermato-venereology conference in May 2007) and a dermatoscopy course in November 2007. The meeting in May 2007 was reported in British Journal, Expert Review of Dermatology.

There is no specific Bosnian journal of dermatology but there is a Bosnian Journal of Basic Medical Sciences. This was first published in 2002 by the Association of Basic Medical Sciences of the Federation of Bosnia & Herzegovina. The journal is indexed in: CAB Abstract/Global Health databases and Index Medicus/MEDLINE. Its Editor-in-Chief is Muzaffer Mujic, Deputy Editor Potkonjaka Dubravka, Secretary: Begovic Begler and Advisory Board President Berberovic Ljubomir.

Contact
Muzaffer Mujic: muzafermujic@yahoo.co.uk.
Foundation
The Society was founded in 1984 and currently has about 500 members. Associate Membership is open to all veterinarians while Affiliate Membership is open to all non-veterinarians who are interested in veterinary dermatology. Information on membership and application forms can be found on the Society’s website: www.esvd.org.

Scope and purpose
The ESVD is a non-profit making organisation with the following aims:
1. To promote veterinary dermatology in all animal species, in both clinical and non-clinical fields
2. To improve standards of diagnosis and treatment
3. To encourage the exchange of information
4. To contribute to the research and teaching of veterinary dermatology at postgraduate level

The ESVD organises an annual congress in three out of every four years, each time in a different European country. The next meeting will take place in Bled, Slovenia, in September 2009. The congresses are held over three days and include specialised/scientific and continuing education programmes.

Each year the ESVD also organises two or three advanced workshops of 3-4 days’ duration for a limited number of participants (30-50 persons) on basic dermatological science (skin biology, immunodermatology, dermatopathology), on clinical topics (clinical pathology, dermatological therapy, skin oncology) or species-orientated (equine dermatology, canine dermatology, feline dermatology, avian and exotic pets).

The ESVD supports research in the field of veterinary dermatology by offering an annual grant of €15,000. Guidelines for application to the ESVD grant can be found on: www.esvd.org.

The ESVD’s journal, Veterinary Dermatology, is the only international publication entirely dedicated to veterinary dermatology. The journal currently has an impact factor of 1.393 and contributions from researchers outside the veterinary world are most welcome. It is published six times per year and is complimentary for all ESVD members and associated veterinary dermatology organisations. A sample issue of the journal can be viewed for free on: http://www.blackwellpublishing.com/vde

Contact
Ian Mason, ESVD Treasurer and Membership Secretary
c/o 89 Queen Street
Newton Abbot
Devon TQ12 2BG, UK
Fax: +44 (0)1626 335135
E-mail: ian.mason@vetderm.co.uk
www.esvd.org

Dermatology and all other clinics in the Clinical Center. We are now trying with great difficulty to make up for everything lost. One of the steps in that direction has been the acquisition of an apparatus for dermoscopy, Mole max II, which was formally put in use on 14 May 2006. Another step was to organise the 1st International Bosnia and Herzegovina Dermato-venereology Conference which was held in May 2007 with great success.

Today
Dermatology in Bosnia & Herzegovina faces a number of challenges: there are 100 dermatologists in hospitals in the country and only 20 in private practice. But the main problem is the lack of funds to buy equipment and train doctors.

We have established co-operation with Austrian dermatology clinics in Graz and Vienna, as well as with a Turkish dermato-venereology clinic in Istanbul. This gives us the possibility to update our knowledge and educate our doctors at a reasonable cost.

Ass Prof Faruk Alendar PhMD
Chief of Dermato-venereology Clinic
and Dr Hana Helppikangas
Clinical Center University of Sarajevo
Bosnia & Herzegovina
The Swiss Psoriasis and Vitiligo Association (SPVG) was founded in 1974. It is the only organisation in Switzerland with a commitment to patients who suffer from psoriasis or vitiligo. Its goals are to involve more youngsters and children afflicted by psoriasis and vitiligo and to develop the website as a major resource tool, including forums and chat rooms.

At present, the Association has 1,200 members. They deal with diverse questions and problems in connection with psoriasis and vitiligo. Furthermore, well-known doctors and specialists are available in the form of a scientific council.

This non-profit organisation regularly informs its members about medical, legal, financial or economic matters and advocates the patients' interests vis-à-vis medical insurances or authorities. The SPVG also tries to acquaint the public with the specific problems encountered by psoriasis and vitiligo patients by means of lectures, exhibitions and meetings.

The bi-monthly magazines Hautsache (literally: skin-matters) in German and La peau surtout in French are included in the membership fees. Those members who wish to get into contact with other members can join regional groups all over Switzerland. Here, they exchange experiences or just enjoy a good meal with others afflicted by the same illnesses.

Moreover, informative lectures and seminars by well-known medical specialists, doctors and other experts are presented on a regular schedule and at different venues.

The SPVG is a member of the European Association of Psoriasis (EUROPSO) and the International Federation of Psoriasis Associations (IFPA) and also supports World Psoriasis Day, held in October each year, with official street stalls in main Swiss towns.

Claudia Rohr

Contact
Adelheid Witzeling
President
SPVG
Scheibenstr. 20
CH-3000 Bern 14
Telephone: +41 (0)31 359 90 99
E-mail: info@spvg.ch
www.spvg.ch
In September 2005, the 3rd International Workshop for the Study of Itch was held in Heidelberg, Germany. The largest meeting of its kind, the workshop had in attendance 200 scientists and physicians from throughout the world interested in itch.

This workshop was the location for the official launch of the International Forum for the Study of Itch (IFSI), the first international society that exclusively focuses on itch research. The IFSI is a multidisciplinary international association for clinical practitioners, researchers and scientists from all medical fields dedicated to improving the understanding and treatment of itch for the benefit of suffering patients worldwide.

Advancing research
The main mission of the non-profit organisation is to advance itch-related research and education and to promote treatment and clinical efforts to help alleviate this debilitating symptom. In addition to managing all future international workshops for the study of itch, IFSI will also disseminate new information about itch to its members, the international medical community and the public at large through various media.

Global focus
IFSI conducts international meetings every second year; the next to be held in Tokyo in October 2009 (organiser: Prof Kenji Takamori) where researchers will present the latest findings in the field. The official journal of the IFSI is the Acta Dermato-Venereologica, where an Itch Section with IFSI members acting as section editors was established. This is the first journal worldwide with a dedicated itch section. ISFI supports the publication of high quality papers in this section by covering the publication costs on request.

Moving forward
During the meetings, the Board members were elected: the first President and founder of IFSI was Gil Yosipovitch from 2005-2007; during the 4th International Workshop for the Study of Itch in September 2007 in San Francisco, Sonja Ständer was elected as President. The current Board members of IFSI are: Sonja Ständer (President), Alan Fleischer (Treasurer), Elke Weisshaar (Secretary), Earl Carstens, Kenji Takamori, Thomas Mettang, Jacek Szepeitowski and Gil Yosipovitch. A membership form can be requested from sonja.staender@uni-muenster.de or from the home page www.itchforum.net.

Contact
Prof Dr Sonja Ständer MD
Clinical Neurodermatology
Department of Dermatology
University of Münster
Von-Esmarch-Strasse 58
D-48149 Münster
Germany
Tel: +49-251-8356534
Fax: +49-251-8356522
E-mail: sonja.staender@uni-muenster.de
www.itchforum.net
Delegate’s view

“I am very happy I have not missed this memorable event, despite coming two days earlier from the International Investigative Dermatology event in Kyoto. Istanbul is an amazing city and the perfect weather conspired against regular attendance of the meeting. However, the organisers prepared a very compact, but with high scientific impact, programme which more and more resembles the traditional autumn EADV Congress.

I would like to point out the very interesting Workshop on Traditional Therapies from East to West. It was most useful to listen to experience from delegates coming from different parts of the world on so-called traditional therapies for most common skin diseases like psoriasis, acne or rosacea.”

Anna Zalewska (Lodz, Poland)
sium: ‘Bridging the Continents’
22–25 May 2008, Istanbul
a successful meeting

themselves by listening to the Enbe Orchestra and dancing.

Professor Gürer, the Chair of the Symposium, stated that Turkey and the Turkish Dermatology Society had proved that they could organise bigger events and implied that Istanbul would be a candidate for the first EADV congress to be voted for. Along with best wishes for its success, the closing ceremony ended with the EADV flag being presented to Professor Dan Forsea, who will be organising the Bucharest Symposium.
Abstracts of candidates’ standardised election statements, presented in alphabetical order. Full versions are available at www.eadv.org and will be sent individually to all voting members.

Louis Dubertret (France)

Dermatology is witnessing a weakening process in most European countries and we need a strong EADV to support our specialty.

In order to strengthen the EADV, our organisation must become progressively the federation of national dermatological societies. The diversity of experiences is one of our main sources of wealth, if we are able to confront our opinions, to identify important unsolved questions and to work together.

To support these exchanges, the EADV must develop European Task Forces co-ordinating National Task Forces, with the aim to connect dermatologists, to develop research programmes and to obtain grants from the EU. These Task Forces ought to be involved in the organisation of EADV meetings’ scientific programmes.

The EADV must contribute, in close collaboration with UEMS, EDF and ESDR, to the development of dermatology through the education of residents. We must also increase the number of grants helping residents to attend EADV meetings.

Our only political strength is our ability to treat our patients. Thus, we must develop strong and ethical relations with our partners to support therapeutic progress: patients associations, pharmaceutical industries and national and European health agencies.

As President and founder of the Fondation René Touraine, as well as during my presidency of the European Dermatology Forum, I have discovered the wonderful diversity of dermatologists and I am passionate about strategies on how to connect them and take advantage of the variety of opinions to improve skin care for our patients.

I would like to use this experience to help the development of EADV, in line with the wonderful work of my predecessors.

Jana Hercogová (Czech Republic)

I would like to serve each and every European dermatovenereologist to give him/her:

1. Feelings of togetherness, friendship, and fruitful co-operation
2. Equal chances to be listened to, to share knowledge, to lecture, to publish personal observations, scientific results
3. Fair support to those who have not been privileged in the past and now need help in education, skills, exchange programmes and research co-operations
4. Proper direction to grow professionally, ethically, and personally in our European dermatology community.

How can we achieve these goals? Our Academy has enlarged by national society members. It should be now promoted like the society where:

1. All members would get a common voice.
2. Intensive exchange programmes
3. Educational events held at each country and
4. More money devoted to scholarships should be planned and realised.

I have served our Academy for five years on the Board and on the Executive Committee. In 2002 I served the Academy as Congress President in Prague. The expectations were for a maximum 3,000 participants and profit for the EADV of up to €200,000. Together with my colleagues of the local organising committee and the leadership of the EADV we were able to double the expectations. We attracted more than 6,000 participants to Prague (six weeks after a disastrous flood), we made a profit of more than €400,000, and, last but not least, it was the first congress in the history of European dermatology where 1,200 colleagues from previous communist Eastern countries attended. This opened a new era for the EADV.
President-Elect Candidates

Frank Powell (Ireland)

Our specialty is under threat throughout Europe! Health administrators and insurance companies “economise” by denying our members adequate facilities or compensation for carrying out their work.

My experience as a clinician in private practice and in academic dermatology has given me a unique understanding of the dangers facing our specialty in both of these areas. Working in the EADV with colleagues from many different European countries as a Board member, organiser of the 1997 EADV Dublin Congress, and as Secretary General has provided me with the background needed to undertake these and other challenges as President of the EADV.

The EADV must become proactive in promoting dermatology and venereology at EU and national levels! We need to be the focus for skin care advocacy at a European level by high profile media campaigns and by linking with responsible patient organisations. We must emphasise the unique training and skills of our members and what we are able to offer patients with diseases of the skin.

If elected I will work hard to promote our specialty and our Academy. I will ensure that the EADV remains a specialist organisation and that the democratic processes within the EADV are operated in a fair and transparent way. I will work with colleagues from other European countries to help our Academy to grow stronger in membership and in educational events so that our members can continue to provide patients with the best available care.

Andris Rubins (Latvia)

It is a great honour, challenge and responsibility to be the President of EADV, since the President has the power and opportunity to influence the rising of prestige of EADV, its development both in scientific and practical ways, as well as its growth.

Now, when looking back to all the years, we can see the enormous work that has been done since 1987 when EADV was founded. Nevertheless, it seems that currently EADV is unable to keep pace with the EU enlargement process.

The strength of EADV must be reinforced by using the great opportunities of the enlargement of EADV towards Eastern Europe by giving the chance to join for new members from the Baltics, as well as from Russia, Ukraine and other CEEDVA countries. In order to achieve that, EADV as an organisation has to be promoted in these countries - by organising the EADV congresses in these countries and by directly involving the specialists from these countries in EADV Congress work. EADV must become the bonding organisation between all the European countries.

The famous Latvian poet Rainis said, “Those who change will last”. It is time for the EADV to change and I am willing to put in all the efforts I can for the sake of further development and growth of EADV. I am ready to accept the honour of being elected as the President and I strongly believe I am by all means the appropriate candidate for this post since I know the history of EADV and have seen its development; I am well aware of the current situation and have a clear vision for the further development and growth.
The task force led by Fenella Wojnarowska and Sarolta Karpati has achieved its first aim:

- Patient information about particular dermatoses and physiological changes that may be pregnancy-related or a problem to pregnant women

Our large team has produced a number of information leaflets to help pregnant women and their dermatologists and venereologists. Dr Gudula Kirtschig co-ordinated this project as so many people contributed.

Patient information has been produced and is now on the EADV website and will be available on the Patients’ Corner as soon as it is up and running.

There are 8 patient information leaflets available:

- Common skin changes during pregnancy
- Specific dermatoses of pregnancy
- Atopic eruption of pregnancy (AEP)
- Polymorphic eruption of pregnancy (PEP)
- Pemphigoid (Herpes) Gestationis (PG)
- Intrahepatic Cholestasis of pregnancy (ICP)
- Skin diseases in pregnancy
- Moles and malignant melanoma
- Mollusca contagiosa
- Scabies

These have been produced in English and will be translated into other European languages.

Treatment advice for pregnant women and their physicians:

This links to the current EADV/EDF project on guidelines for the safe use of topical steroids in pregnancy and a preliminary draft has been produced.

This has been a very exciting task force to be part of and has accomplished much since our inaugural meeting in Vienna.

Fenella Wojnarowska
Leader
Task Force on Skin Disease in Pregnancy

Media training available during EADV Paris Congress 2008

Would you like to try out your television interview technique? If so, take advantage of personal, one-to-one training sessions which will be available for candidates at the EADV Congress in Paris. We hope to have media-trained doctors who can conduct these interviews in a range of languages. Book a place and see how you cope on camera.

The workshop W43 is scheduled for Saturday, 20 September from 14.45 to 16.15 and will be held in Meeting Rooms 342A & 342B.

For further information and to book your place, please contact Stefanie Blum at stefanie@eadv.org

Dr Klaus Fritz
Chairman
Dr Colm O’Mahony and Dr Myrto Trakatelli
Co-Chairs

Amércio Manuel Da Costa Figueiredo
(Portugal)

Amércio Manuel Da Costa Figueiredo graduated from the University of Coimbra in Medicine in 1977, becoming a specialist in dermatology and venereology and clinical pharmacology in 1988. He was a Fellow at the Department of Dermatology, University of Barcelona (Spain) in 1987.

In 1995 he was awarded a PhD in Dermatology and Venereology from the University of Coimbra’s Faculty of Medicine. In 2003, he was appointed a specialist in the Management of Health Services by the Portuguese Physician Council.
Eczema is the most important and most frequent inflammatory skin disease. Different approaches to diagnosis and treatment in different European countries have been a major concern to clinicians in recent decades.

The Eczema Task Force of the EADV was initiated in 2006 by merging with the former sister society, European Task Force on Atopic Dermatitis (ETFAD). ETFAD was founded 17 years ago by a group of paediatric dermatologists (D Atherton, C Gelmetti, J Harper, B Kunz, R Lever, A Oranje, J-H Saurat, J-F Stalder, A Taieb) at the 3rd ESPD Congress and at the Symposium on Atopic Dermatitis organised in Bordeaux (1990), on the initiative of Alain Taieb and Jean-François Stalder.

Later, at the atopic dermatitis meeting organised by Georg Rajka in Norway, dermatologists including T Bieber, T Diepgen, A Giannetti, T Reunala and J Ring joined the group. The members of ETFAD (until now mainly dermatologists and paediatricians) are active in different clinical and research activities in the field of eczema (atopic dermatitis) and meet regularly for information exchange. The well-known SCORAD device for severity scoring of the disease was developed by ETFAD members. The group conducted studies including the largest multi-centre trial on the atopy patch test to evaluate this diagnostic method. A formal affiliation of ETFAD as a working group/sister society to the EADV was accomplished in 2002. Due to the pan-European membership, Task Force meetings were regularly held on the occasion of an EADV congress. The next meeting will take place during the 17th EADV Congress in Paris.

**Scope**

- Exchange of current information on eczema and related fields to improve international standards in diagnosis and therapy.
- Networking with national allergy societies.
- Open to all EADV members interested and active in the field of different eczematous diseases.
- Serving as an independent platform for international multi-centre studies.

**Current activities**

- Symposia: since 2001, the Task Force presented the work of members at its own symposium at every EADV Congress. The abstracts were published in the JEADV abstract book /CD-ROM. This tradition continues under the new name ETFAD / EADV Eczema Task Force.

- Guidelines: a European consensus on the treatment of atopic eczema has been published in our journal JEADV in 2006 (ongoing project), a position paper on atopy patch test in cooperation with EAACI/GA2LEN in Allergy 2006.
- Patient education: members are active in different national patient education projects, including website development and outcome evaluation measures.

**Ulf Darsow**

Dept of Dermatology and Allergy
Biederstein
Technical University Munich
Biedersteiner Str. 29
D-80802 München, Germany
E-mail: ulf.darsow@lrz.tum.de

**Alain Taieb**

Service de Dermatologie
Hôpital St André
1 rue Jean Burguet
33075 Bordeaux Cédex, France
E-mail: alain.taieb@chu-bordeaux.fr
European Dermato-epidemiology Network (EDEN)

The European Dermato-epidemiology network (EDEN) is an active group of researchers in the field of dermato-epidemiology. The group started working together in 1995. It is not a society with a membership but consists of a steering group with contacts in many European countries. The aims of the group are to expand the role of epidemiology in dermatology, to share expertise and to produce high quality multi-centre collaborative work, including the dissemination of information, teaching, training and organising working groups to address important research questions about the distribution, causes and treatment of skin disease.

EDEN holds triennial congresses, the most recent being in Venice in October 2004, in conjunction with the International Dermatoepidemiology Association, and the next congress will be held in Nottingham (UK) in September 2008 (www.idea2008.net).

Projects

EDEN is currently involved in six active projects at various stages of development and completion. Briefly, the project outlines are as follows:

Procedures in dermatology
A CD of “Procedures in dermatology” has been prepared by Dr Luigi Naldi in conjunction with EDEN colleagues. This teaching tool focuses on the evidence-based approach to practical procedures in dermatology. The tool is designed for dermatologists, primary care physicians, medical students and health care workers. It is hoped that this will be developed by a major publisher and that the final product will become available during 2008.

Hand eczema
The EDEN group has recently published a survey of trials on interventions for hand eczema led by Pieter-Jan Coenraads. This survey has been continued into a full Cochrane systematic review and is about to be submitted. This review has led to the development of a complete database of the randomised controlled trials (RCTs) in hand eczema. The list of RCT titles is available on the EDEN website leading to a useful source of information for future researchers and the possibility of future collaborations.

Psoriasis
Luigi Naldi also led the work on the compilation of a database of all randomised controlled trials of interventions for psoriasis which is currently being updated. The initial EDEN survey of psoriasis trials from 1977 to 2000 was published in the Journal of Investigative Dermatology. This updated review will be submitted for publication in 2008.

Quality of life
EDEN recently hosted a major meeting to discuss quality of life outcome tools in dermatology. This event, led by Jean-Jacques Grob, was held in Paris in September 2006 before the ESDR and was attended by many key international experts in the field. The aim of the meeting was to review currently available tools and to assess whether there was a need to develop a new trans-cultural tool for international studies. A literature review will follow and further collaborative discussions are planned.

Fragrance study
A pre-pilot study of the prevalence of fragrance allergy in Europe has been completed by the group. Data from this study was presented at the European Society of Dermatology Research (ESDR) meeting in Paris in September 2006. This led to the development of a protocol for a pilot study. Currently, funding for this study is being sourced with a view to early commencement of the main pilot study.

Systematic review of outcome measures in eczema
A published systematic review of outcome measures in eczema by Charman et al has been updated (Schmitt et al J Aller Clin Immunol 2007; 120(6): 1389-98). The aim of this update was to identify a set of minimum outcome measures for use in clinical studies in eczema. Following completion of the systematic review, a Delphi conference is being planned to make recommendations to the international community.

Meetings

EDEN will continue its successful collaboration with the ESDR. This involves including epidemiology in the plenary sessions and a scientific symposium held alongside the ESDR main meeting. EDEN committee members are also actively involved in other major dermatology meetings including the EADV.

For further information about EDEN activities and sources cited above, please visit our website at: http://orgs.dermis.net/content/e02eden/e527/e528/index_ger.html

Contact

Sinéad Langan
Centre of Evidence-based Dermatology
C floor, South Block
Queen’s Medical Centre
Nottingham NG7 2UH, UK
Tel: +44 (0)115 8231040
Fax: +44 (0)115 8231046
E-mail: sinead.langan@nottingham.ac.uk
Update from the Secretary General

From Istanbul to Paris

May dear friends,

We have barely had time to settle back into our offices and work routine after that marvellous meeting in Istanbul when Paris reminds us it is only three months down the road!

Istanbul

First the plaudits, and greatly deserved ones at that. Our Turkish hosts were simple excellent in every possible respect. The simple but meaningful opening ceremony followed by a lavish reception where nobody had to wait in line for a drink or a bite (many bites in fact) was outstanding and here lessons are to be learned. Our accommodation was of fine quality, the organisation at the conference centre was highly professional, as was the academic quality of the meeting. The conference banquet in such unusual surroundings proved to be a high point of our stay in the Queen of Cities. Well done all. And I am sure it will only be a matter of a few years before Istanbul is chosen to host a larger EADV academic meeting.

While delegates and accompanying persons sampled the various delights of Istanbul, the Officers, Board members, and staff had a busy time indeed. With two meetings of the Executive Committee, a Board meeting, an Extraordinary General Meeting, plus numerous committee meetings, it was no great surprise that on leaving the hotel a colleague I had not yet met asked me if I had been at the whole meeting - such is life.

The outcomes

Board meeting

Apart from long discussions concerning the amendments to the Statutes, a number of important announcements were made and decisions taken:

Sponsorship

• A contract was signed with ten main sponsors for three years and with another sponsor for one year.

Membership

• The total number of members has increased to more than 3,030, an increase of 50% since 2004.
• National society membership: a number of societies have expressed themselves positively on joining this scheme representing approximately 10,000 members. A further number with approximately 5,000 members are actively exploring the option of joining. The Board confirmed that the fee for group membership for the national societies will be £5 for each society member per annum.
• A cordial meeting of the EC and Board with a number of the national presidents took place at the end of the Board meeting and this colloquium will be a permanent feature in future congresses.

Congresses & Symposia

• For 2010 and 2011 the donation to the local organising committee be reduced to 20%. As EADV will probably have taken full responsibility for organising the 2012 Congress, the Finance Committee proposes that from 2012 the donation be a fixed sum depending on the economic success of the congress. Regardless symposia, these remain unchanged for the time being.
• When two candidate bids have both demonstrated their capability to organise a successful EADV meeting to the satisfaction of the visiting site inspection team (as evidenced in their site visit report and presentation), the second placed candidate should be offered the subsequent year’s meeting.
• Lisbon will host the 2011 Congress, following a close decision (19 to 17 votes). Riga will host the 2012 Congress as a result of the decision above.

Election of President-elect

• Four validly nominated candidates are standing for this position: Louis Dubertret (France), Jana Hercogova (Czech Republic), Frank Powell (Ireland) and Andris Rubins (Latvia). We are fortunate to have such outstanding candidates and their election statements can be found on pages 14-15; further details and voting procedures can be found on the EADV website (www.eadv.org). Both electronic and postal votes will be possible but there will be no voting at the Annual General Meeting in Paris. The independent organisation ERS of London will be responsible for the technical arrangements of the electoral process.

It is hoped that 2009 will see the dawn of a stronger EADV, confident that it is legitimately representing the huge majority of European dermato-venereologists, and now assured of a secure financial base on which to build further and sustain its mission towards the physicians and scientists in the front line of our specialty, as well as towards those affected or who may be at risk of developing skin/venereal disease. Additional benefits will accrue from the increasingly greater involvement of the EADV central office in meetings’ organisation.

A bientôt,

Joseph L Pace MD
Secretary General

➤ Please send your suggestions, feedback and contributions to EADV News Administrative Officer, Stefanie Blum at: stefanie@eadv.org

19
Beyond fashion

Send your pictures to **EADV News** ...

Send us pictures of Dermato-Venereology practice to: stefanie@eadv.org

A selection of these images will be published in upcoming issues of **EADV News**.

Important note: Pictures must be submitted in eps, jpg, or tif format. Please ensure that your pictures are high resolution images: 300 dpi

---

**Squamous Cell Carcinoma Secondary to Buruli Ulcer**

Buruli ulcer is an emerging infectious disease caused by Mycobacterium ulcerans (MU). Endemic foci have been reported in some regions of Africa, Australasia and South America, but it is exceptional in Europe (Fig.1-4). In tropical rain forests MU infection is acquired through small cutaneous injuries by the biting of water insects or rarely by snails, small fishes or biofilm. The first stage of the disease is characterised by a cutaneous firm, non-tender papule, evolving after a variable period into a scarcely deep ulceration, with coalescent necrosis and typically undermined edges, usually located on the upper or lower limbs (Fig.1). When a spontaneous healing occurs, it results in ankylosis and contractures; more rarely, it evolves towards squamous cell carcinoma (SCC) (Fig.2 and 4) or local or multifocal osteomyelitis through MU hematogenous spread. Histopathological features show chronic polymorphic infiltrate associated with areas of necrobiosis and fibrosis in the dermis (Fig. 2 and 3). Ziehl-Neelsen stain identifies acid-fast bacilli in cutaneous specimens. Culture is difficult. At present, protein chain reaction (PCR) represents the elective way to detect MU. The therapy requires early and radical PCR-guided surgical excision to avoid local relapses or complications.

---

**Dates for your Diary**

---

**Calendar of Events**

---

> **2008**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>24th Conference on Sexually Transmitted Infections and HIV/AIDS - IUSTI Europe 2008</td>
<td>4-6 September 2008</td>
</tr>
<tr>
<td>5th IDEA Congress</td>
<td>7-9 September 2008</td>
</tr>
<tr>
<td>2nd International Conference on “Sebaceous Gland, Acne and Related Disorders Basic and Clinical Research, Clinical Entities and Treatment”</td>
<td>13-16 September 2008</td>
</tr>
<tr>
<td>17th EADV Congress</td>
<td>17-21 September 2008</td>
</tr>
<tr>
<td>Peripheral T-cell Lymphoma Forum</td>
<td>18-20 September 2008</td>
</tr>
<tr>
<td>Psoriasis: From Gene to Clinic</td>
<td>4-6 December 2008</td>
</tr>
<tr>
<td>COSMODERM XIIIth - Joint Meeting of ESCAD and the Hellenic Society of Dermatology &amp; Venereology</td>
<td>12-14 December 2008</td>
</tr>
</tbody>
</table>

---

> **2009**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>67th Annual Meeting AAD</td>
<td>6-10 March 2009</td>
</tr>
<tr>
<td>6th EADV Spring Symposium</td>
<td>23-26 April 2009</td>
</tr>
<tr>
<td>12th World Congress on Cancers of the Skin</td>
<td>3-6 May 2009</td>
</tr>
<tr>
<td>Photodermatology Meeting &amp; Photopatch Test Course</td>
<td>18-19 September 2009</td>
</tr>
<tr>
<td>18th EADV Congress</td>
<td>7-11 October 2009</td>
</tr>
<tr>
<td>11th IUSTI World Congress</td>
<td>9-12 November 2009</td>
</tr>
</tbody>
</table>

---

> **2010**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>7th EADV Spring Symposium</td>
<td>13-16 May 2010</td>
</tr>
<tr>
<td>19th EADV Congress</td>
<td>6-10 October 2010</td>
</tr>
</tbody>
</table>
Dates to remember
Abstract Submission Deadline
November 28th 2008
Abstract Evaluation Announcement
January 15th 2009
Reduced Registration Fee Deadline
January 10th 2009
Deadline for hotel reservation
February 15th 2009

6th EADV Spring Symposium
Rin Grand Hotel Conference Center
Bucharest, Romania, April 23 - 26, 2009

Symposium Secretariat
Romania Travel Plus
56 Tudor Ștefan St., Sector 1, Bucharest 011658, Romania
Tel: +40 21 230 42 82; +40 21 230 51 10; Fax: +40 21 230 50 42
E-mail: info@eadvbucharest2009.com

General Information: info@eadvbucharest2009.com
For Exhibition: exhibition@eadvbucharest2009.com
For Registration: registration@eadvbucharest2009.com
For Hotel Reservation: hotel@eadvbucharest2009.com
Symposium website: www.eadv.org/bucharest2009

Skin and Quality of Life

www.eadv.org/bucharest2009
Control the itch, tame the eczema.

Protopic® provides effective control of eczema.

- Fast relief of itch
- Effective control of moderate and severe atopic eczema
- For short-term and intermittent long-term treatment in adults and children (≥ 2 years)

References:

AABBREVIATED PRESCRIBING INFORMATION:
Protopic® 0.03% ointment: Calcipotriol monohydrate (Calcipotriol monohydrate) ACTIVE INGREDIENT: Protopic® 0.03% ointment (1g) contains 0.03 mg of calcipotriol as calcipotriol monohydrate (0.03%). Protopic® 0.05% ointment: Calcipotriol monohydrate (Calcipotriol monohydrate) ACTIVE INGREDIENT: Protopic® 0.05% ointment (1g) contains 0.05 mg of calcipotriol as calcipotriol monohydrate (0.05%). Protopic® 0.05% ointment: treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies (such as topical corticosteroids). DOSAGE AND METHOD OF USE: Protopic® should be applied twice a day for up to 3 weeks. Alternatively, the frequency of application can be reduced to once a day, until clearance of the lesion. The treatment of atopic dermatitis should be terminated if symptoms are not improved after 4 weeks, if no improvement is seen after 2 weeks of treatment, or if the patient is not willing to continue treatment. Treatment should not be discontinued if treatment is not continued. Instructions for the use of Protopic® are correct for use in children (≥ 2 years).

The patient should be instructed to apply the medication to the affected skin as directed by the healthcare provider. Treatment should not be discontinued if no improvement is seen after 4 weeks.

SIDE EFFECTS: The most common side effects of Protopic® are skin irritation and sensitivity. If these symptoms persist, treatment should be discontinued. The patient should be instructed to discontinue treatment if symptoms persist for more than 3 days.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.

WARNINGS/CAUTIONS: Protopic® is contraindicated in patients who are hypersensitive to any component of the medication. Protopic® is not recommended for use in children under the age of 12 years or in patients with severe eczema. Protopic® is not recommended for use in patients with a history of sensitization to the active ingredient.

The patient should be informed that the use of Protopic® can cause skin irritation and sensitivity. The patient should be instructed to report any adverse reactions to the healthcare provider.